1. 2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC). (September 2015) Authors: Hurwitz, H.; Zafar, Y.; Kozloff, M.; Hubbard, J.; Van Cutsem, E.; Bennouna, J.; Arnold, D.; Bekaii-Saab, T.; Srock, S.; Revil, C.; Fish, S.; Barue, V.; Grothey, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). (September 2015) Authors: Oza, A.M.; Selle, F.; Davidenko, I.; Korach, J.; Mendiola, C.; Gocze, P.; Pautier, P.; Chmielowska, E.; Bamias, A.; DeCensi, A.; Zvirbule, Z.; Gonzalez-Martin, A.; Hegg, R.; Joly, F.; Zamagni, C.; Gadducci, A.; Deurloo, R.; Revil, C.; Robb, S.; Colombo, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗